United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment

Table 1 Any time resource utilization by neuroendocrine tumor type¹n (%)

	All NET (n = 110)	GI/lung NET (n = 70)	pNET (n = 40)
Treatments
Surgery	50 (45.45)	30 (42.86)	20 (50.00)
Chemotherapy2	42 (38.18)	30 (42.86)	12 (30.00)
PRRT	6 (5.45)	6 (8.57)	0 (0.00)
Somatostatin	86 (78.18)	54 (77.14)	32 (80.00)
Targeted therapy3	7 (6.36)	5 (7.14)	2 (5.00)
Resources
Hospitalizations	62 (56.36)	40 (57.14)	22 (55.00)
Ultrasounds	42 (38.18)	22 (31.43)	20 (50.00)
CT scans	79 (71.82)	53 (75.71)	26 (65.00)
Helical scans	42 (38.18)	27 (38.57)	15 (37.50)
Other imaging tests4	64 (58.18)	41 (58.57)	23 (57.50)
Bio marker5	73 (66.36)	47 (67.14)	26 (65.00)
Other lab tests6	70 (63.64)	41 (58.57)	29 (72.50)
Physician visit	109 (99.09)	40 (100.00)	69 (98.57)

¹A patient was counted (once) if that individual utilized a resource at any stage of their disease;

²Chemotherapy includes 5-fluorouracil, actinomycin-D, capecitabine, carboplatin, cisplatin, cyclophosphamide, dacarbazine, doxorubicin, etoposide, gemcitabine, irinotecan, mitotane, oxaliplatin, streptozocin, temozolomide and vincristine;

³Targeted therapy includes everolimus, sunitinib, imatinib, and bevacizumab; the data collection form captured these therapies under the heading “other treatments”;

⁴Other imaging includes positron emission tomography, stereotactic radiosurgery, metaiobenzylguanidine, magnetic resonance imaging, and chest X-ray;

⁵Biomarkers include neurotensin, chromogranin A, pancreatic polypeptide, neurotensin, plasma serotonin, vasoactive intestinal polypeptide, ghrelin, human chorionic gonadotropin, Ki-67, 5-hydroxyndoleacetic acid, plasma substance P, total and free T4;

⁶Other lab tests include serum glucose, complete blood count, blood urea nitrogen, serum creatinine, and lipid profile were captured. PRRT: Peptide-receptor radionuclide therapy; NET: Neuroendocrine tumor; pNET: Pancreatic NET; GI: Gastrointestinal tract; CT: Computed tomography.